An agenus-discovered first-in-class ilt4 antibody, mk-4830, enters phase 2

Lexington, mass., nov. 10, 2020 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that a milestone payment of $10m from merck has been triggered with the advancement of an ilt4 antibody, mk-4830, into a phase 2 clinical trial. agenus discovered this novel checkpoint antibody, designed to target immune-suppressive myeloid cells in the tumor microenvironment for the treatment of advanced solid tumors, and licensed the molecule to merck.
AGEN Ratings Summary
AGEN Quant Ranking